Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Subtyping of Small Cell Lung Cancer using ChIP-seq of plasma cell-free nucleosomes and matched tumor transcriptomes

ABSTRACT: Subtyping of Small Cell Lung Cancer using ChIP-seq of plasma cell-free nucleosomes and matched tumor transcriptomes

PROVIDER: PRJNA1106082 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Subtyping of Small Cell Lung Cancer using plasma cell-free nucleosomes

Project description:Subtyping of Small Cell Lung Cancer using plasma cell-free nucleosomes

| PRJNA1006798 | ENA

Subtyping of Small Cell Lung Cancer using ChIP-seq of plasma cell-free nucleosomes and matched tumor transcriptomes

Project description:Subtyping of Small Cell Lung Cancer using ChIP-seq of plasma cell-free nucleosomes and matched tumor transcriptomes

| PRJNA1106083 | ENA

Cerebrospinal fluid cell-free DNA methylomes subtyping pediatric medulloblastoma

Project description:Cerebrospinal fluid cell-free DNA methylomes subtyping pediatric medulloblastoma

| PRJNA737500 | ENA

Molecular subtyping of breast cancer by transcription profiling

Project description:Breast cancer was one of the first cancer types where molecular subtyping led to explanation of interpersonal heterogeneity and resulted in improvement of treatment regimen. Several multigene classifiers have been developed and in particular those defining molecular signatures of early breast cancers possess significant prognostic information. Hence since 2014, molecular subtyping of primary breast cancers was implemented as a part of routine diagnostics with direct impact of therapy assignment. In this study, we evaluate direct and potential benefits of molecular subtyping in low-risk breast cancers as well as present the advantages of a robust molecular signature in regard to patient work-up among high-risk breast cancers.

2017-12-01 | E-MTAB-5724 | biostudies-arrayexpress

Cerebrospinal fluid cell-free DNA methylomes subtyping pediatric medulloblastoma

Project description:Medulloblastoma (MB) is an embryonal tumor of the cerebellum and a highly malignant childhood brain tumor. Cell-free circulating tumor DNA (ctDNA) from the cerebrospinal fluid (CSF) of patients with brain tumors faithfully represent genomic alterations of brain tumors. Distinct epigenetic signatures among subgroups of MB allow us to detect epigenetic alterations in CSF to aid classify and guide therapy of MB tumors. Here, we evaluate DNA methylation of ctDNA derived from small amount of CSF (200 µL) and matched tumor DNA from four subtypes of MB patients. We find highly concordance of DNA methylation between CSF ctDNA and tumor DNA in a subtype manner. Our results show that CSF ctNDA methylation can be a minimal invasive precisely method to assess epigenetic alterations of MB in a subtype manner, which is complementary to current diagnoses of MB tumors.

2023-06-01 | GSE178169 | GEO

Colorectal Adenomas and Consensus Molecular Subtyping

Project description:Consensus molecular subtyping in adenomatous and serrated polyps

2018-12-19 | GSE108317 | GEO

ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin.

Project description:Cell-free DNA (cfDNA) in human plasma provides access to molecular information about the pathological processes in the organs or tumors from which it originates. These DNA fragments are derived from fragmented chromatin in dying cells and retain some of the cell-of-origin histone modifications. In this study, we applied chromatin immunoprecipitation of cell-free nucleosomes carrying active chromatin modifications followed by sequencing (cfChIP-seq) to 268 human samples. In healthy donors, we identified bone marrow megakaryocytes, but not erythroblasts, as major contributors to the cfDNA pool. In patients with a range of liver diseases, we showed that we can identify pathology-related changes in hepatocyte transcriptional programs. In patients with metastatic colorectal carcinoma, we detected clinically relevant and patient-specific information, including transcriptionally active human epidermal growth factor receptor 2 (HER2) amplifications. Altogether, cfChIP-seq, using low sequencing depth, provides systemic and genome-wide information and can inform diagnosis and facilitate interrogation of physiological and pathological processes using blood samples.

| S-EPMC7610786 | biostudies-literature

ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells-of-origin

Project description:Cell-free DNA in human plasma provides access to molecular information about the pathological processes in the organs or tumors from which it originates. These DNA fragments are derived from fragmented chromatin in dying cells, and retain some of the cell of origin histone modifications. Here, we apply chromatin immunoprecipitation of cell-free nucleosomes carrying active chromatin modifications followed by sequencing (cfChIP-seq) to 268 human samples. In healthy donors, we identified bone marrow megakaryocytes, but not erythroblasts, as major contributors to the cfDNA pool. In patients with a range of liver diseases, we show that we can identify pathology-related changes in hepatocyte transcriptional programs. In metastatic colorectal carcinoma patients, we detected clinically relevant, and patient-specific information, including transcriptionally active HER2 amplifications. Altogether, cfChIP-seq using low sequencing depth, provides systemic and genome-wide information, can inform diagnosis, and facilitate interrogation of physiological and pathological processes using blood samples.

| EGAS00001004913 | EGA

Clinical subtyping of cancer from plasma based on comprehensive epigenomic profiling

Project description:Clinical subtyping of cancer from plasma based on comprehensive epigenomic profiling

| PRJNA1018575 | ENA

Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis

Project description:Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis

| PRJNA401208 | ENA